These findings offer novel experimental evidence for the molecular mechanisms underlying arsenic-induced liver fibrosis, indicating that targeting IL-17 and NLRP3 can effectively suppress HSC activation (e.g., Figure 5). The gene discussed is IL17A; the disease is Hepatic fibrosis.